Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEYHG9)

Drug Name

Elotuzumab Drug Info

Synonyms

BMS-901608

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Approved	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting SLAM family member 7 SLAMF7 (CS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PVX-410	DM6DK9A	Multiple myeloma	2A83	Phase 2	[2]
BCMA-CS1 cCAR	DMEPHMR	Multiple myeloma	2A83	Phase 1	[3]
CS1-CAR T Therapy	DMU8OCN	Plasma cell myeloma	2A83.1	Phase 1	[4]
ABBV-838	DMZM0T8	Multiple myeloma	2A83	Phase 1	[5]
MB-104	DMRP4BM	Multiple myeloma	2A83	Phase 1	[6]
UCARTCS1	DM2Y4D7	Multiple myeloma	2A83	Phase 1	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8361).
2	Market watch: Upcoming catalysts in Q2 2015. Nat Rev Drug Discov. 2015 Apr;14(4):228.
3	ClinicalTrials.gov (NCT04156269) BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma. U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT03710421) CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Clinical pipeline report, company report or official report of Mustang Bio.
7	ClinicalTrials.gov (NCT04142619) Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01). U.S. National Institutes of Health.